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INTRODUCTION
Osteoarthritis (OA) is a degenerative joint disease character-
ized by progressive articular cartilage loss, subchondral bone
sclerosis, osteophyte formation, synovial membrane changes,
and an increased synovial fluid with decreased viscosity and
lubrication properties. Mechanical, biochemical, and genet-
ic factors are all involved in OA pathogenesis (1).
Non-surgical modalities for OA management include weight
loss, exercise, activity modification, assistive devices, non-
steroidal anti-inflammatory drugs (NSAIDs), analgesics, and
intra-articular glucocorticoid and hyaluronic acid (HA) prepa-
rations (2). NSAIDs and glucocorticoids are the most com-
monly used treatments among these modalities. However,
due to the adverse effects on cartilage and other potential side
effects, the role of NSAIDs in OA management is controver-
sial (3). Cortisone, strong anti-inflammatory agent, is also
limited in use by articular cartilage damage, secondary infec-
tion, and systemic side effects with repeated injections (4). 
HA has been recognized as a safe and efficacious alternative
therapy. It binds to the proteoglycan surface components of
articular cartilage, provides an important boundary layer for
lubrication, prevents cartilage destruction, influences anti-
inflammatory properties, and facilitates cartilage re-arrange-
ment. The efficacy of HA therapy is dependent on OA grade.
While moderate to mild OA is responsive to HA, it is not
effective in cases with considerable effusion or in individuals
with gross architectural changes (7). 
Growth hormone is an important regulator of skeletal grow-
th and bone mineral density. It also stimulates cartilage growth
probably through local and systemic IGF-1 production and
possibly by direct stimulation of cartilage cell proliferation.
Circulating GH or one of its mediators may accelerate osteo-
chondral defect healing by stimulating osseous and chondral
tissue formation (8). Morphoangiogenesis was initially iden-
tified in the knees of adult rabbits undergoing intra-articular
GH injections for articulophyseal cartilage regeneration (9).
In this experiment, the regeneration cascade resulted in the
transformation of central arteries in the subchondral osteones
into tortuous, thin-walled fenestrated capillary structures
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Additive Effects of Intra-articular Injection of Growth Hormone and
Hyaluronic Acid in Rabbit Model of Collagenase-induced Osteoarthritis 
In a rabbit model of collagenase-induced osteoarthritis, the additive effects of intra-
articular recombinant human growth hormone (GH) administration to hyaluronic
acid (HA) were evaluated. After intra-articular collagenase injection, mature New
Zealand white rabbits (n=30) were divided into 3 groups. Group 1 (control rabbits)
received once weekly intra-articular saline injections for 4 weeks. Group 2 rabbits
received 6 mg HA injections, and group 3 rabbits were injected with 6 mg HA and
3 mg recombinant human GH. These injections were initiated 4 weeks after colla-
genase injections. Lameness was observed for 9 weeks after collagenase injec-
tions. Macroscopic and histopathological knee joint findings were also evaluated at
the end of 9 weeks after collagenase injections. Although all animals had lameness
after collagenase injections, the duration and severity of lameness were significant-
ly shorter and less severe in group 3 than group 1 and 2 (P<0.01). Macroscopic
scores showed that femoral condyles of group 3 rabbits received significantly less
cartilage damage than those of groups 1 and 2 rabbits (P<0.01). Histopathological
score was also the lowest in group 3 (P<0.01). These results suggest that co-injec-
tion of intra-articular HA and recombinant human GH is more effective than HA
injections alone in an osteoarthritis model. 
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which contained erythrocytes, histiocytes, stem cells, and
chondrocytes. This morphoangiogenesis might promote gen-
erative and constructive action in joints. The exact mecha-
nisms of intra-articular GH are unclear, but synovial fluid
GH could enhance the proliferation, matrix synthesis, and
differentiation of bone and cartilage cells in vitro (4). In this
study, we evaluated the effects of intra-articular HA and recom-
binant human GH administration of collagenase-induced
OA in rabbits. 
MATERIALS AND METHODS 
Animals 
Male New Zealand white rabbits (n=30) aged 12 weeks
were used in the experiments. Animals were housed in sep-
arate metal cages at a temperature of 23±2℃and a relative
humidity of 45±10%. The animals were allowed free access
to tap water and were fed a commercial rabbit diet. Animal
experiments were performed in accordance with internation-
ally accredited guidelines, and were approved by each labo-
ratory’s Institutional Animal Care and Use Committee. 
Experimental OA model
Experimental animals were anesthetized with an intramus-
cular xylazine injection at a dose of 1.9 mg/kg (Rompun,
Bayer Co., Seoul, Korea) and 46 mg/kg of ketamine (Ketar,
Yuhan Co., Seoul, Korea). The right knee joints of all rab-
bits were shaved and sterilized, and 2 mg collagenase type
II from Clostridium histolyticum (Sigma Co., St. Louis, MO,
USA) was prepared for intra-articular injection. Collagenase
was dissolved in sterile phosphate buffered saline (pH 7.4)
and filtered with a 0.22 mm membrane. The solution was
slowly injected into the right knee joint cavity. The same
collagenase injection procedure was performed 3 days after
the first injection, as previously described (10). 
Drugs administration
Rabbits were divided into 3 groups of 10 rabbits apiece.
The control group (group 1) received once weekly intra-artic-
ular injections of saline (0.6 mL) for 4 weeks. Injections were
given 4 weeks after collagenase injections. Group 2 rabbits
received intra-articular HA (Hyruan-plus
�, LG Life Science,
Daejeon, Korea) injections (6 mg). The HA molecular weight
measured at 3.0×106 Dalton, and it was prepared to a 10
mg/mL concentration. Group 3 rabbits received intra-artic-
ular HA (6 mg) and recombinant human GH (3 mg) injec-
tions. All procedures were performed under general anesthe-
sia (intraperitoneal xylazine and ketamine) and sterile con-
ditions. No post-operative medications were administered.
All animals were euthanized by intravenous injection (sodi-
um pentobarbital, 100 mg/kg) 9 weeks after initial collage-
nase injection. 
Lameness of the affected limb
Clinical observations were performed once daily, on 14:00
in a day. The animals were turned out to the ground of the
area of 2 square meters, then gait was assessed by direct obser-
vation for 20 min individually. In the intact limb, knee and
ankle angles go through a typical flexion and extension cycle
during hoping. Lameness was defined as a non-weightbear-
ing of the affected limb and a losing of typical flexion and
extension cycle during hoping in comparison with contralat-
eral side. The severity of lameness was not quantified. The
times to normal ambulation without non-weigthbearing lame-
ness of affected limb were recorded, and lameness periods
were calculated on each group. Three independent physia-
trists without prior knowledge of the experimental groups
performed the observation.
Gross observation of the damaged area
Knee joints were dissected after euthanasia. The medial
and lateral condyles of the femur and tibia were examined for
gross changes. Cartilage surfaces of the loaded areas of the
femur and tibia were evaluated for degeneration, using the
scoring system by Yoshimi et al. (11). All measurements were
performed on the lateral part of the femoral condyle, which
in the region most affected by collagenase (10). Normal car-
tilage was scored as 0, softened cartilage as 1, fibrillation as
2, erosion as 3, ulceration as 4, and loss of cartilage as 5. 
Histopathological examination
The lateral and medial condyles of the femur and tibia were
fixed with 10% neutral buffered formalin and decalcified
with 20% EDTA. Calcified condyles were embedded in paraf-
fin, and standard frontal sections of 5 mm microsections were
prepared and stained with hematoxylin and eosin in the lat-
eral part of the femoral condyle cartilage according to gross
observation (10). If the stain is not proper, we cut the speci-
men next cartilage surface. Cartilage degradation features
were analyzed using the scoring system modified by Mankin
et al. (12). Histopathological evidence of cartilage degenera-
tion was evaluated by structural scoring (0, normal; 1, surface
irregularities; 2, pannus and surface irregularities; 3, clefts
to transitional zones; 4, clefts to radial zones; 5, clefts to cal-
cified zones; and 6, complete disorganization) and cell sta-
tus (0, normal; 1, diffuse hypercellularity; 2, cloning; and 3,
hypocellularity) of the articular cartilage. Total scores ranged
from 0 (normal) to 9 (complete disorganization and hypocel-
lularity of articular cartilage). All sections were graded by
two independent observers that were kept unaware of the
treatment groups.778 S.B. Kim, D.R. Kwon, H. Kwak, et al.
Statistical analysis
Statistical analysis was performed using the SPSS V. 14.0
software. Results were assessed by analysis of variance for
multi-group comparisons. Scheffe’s post hoc test was used,
and Pvalues <0.05 were statistically significant. 
RESULTS
Lameness period
Side effects including injection site infection, swelling,
anorexia, diarrhea, and vomiting were not observed during
9 weeks evaluation period. Time to recovery of normal ambu-
lation was an average of 26 days in group 1 rabbits, 19.1 days
in group 2 rabbits, and 11.6 days in group 3 rabbits (Table 1). 
Macroscopic score
Macroscopic damages in the femoral condyles of treated
rabbits differ with treatment regime: saline, HA, coinjec-
tion of HA and GH (Fig. 1). All the evaluated group 3 rab-
bits showed smooth surfaces and integration of repair tissues
to the surrounding articular cartilage in the femoral condyles,
suggesting healing without degenerative effects. On the con-
trary, loss of cartilage and erosion were observed in the con-
dyles of group 1 and 2 rabbits. Macroscopic scores in control
and treatment groups are shown in Table 1. HA injected or
HA and GH coinjected groups showed significant lower
macroscopic scores compared with the control group. Con-
sistent with macroscopic features, group 3 rabbits, coinject-
ed with GH with HA, was also lower in macroscopic score
than group 2 injected with HA alone (Table 1).
Histopathological findings
The control group (group 1 rabbits) demonstrated com-
plete disorganization of articular cartilage with apparent
cloning of chondrocytes in the transitional and radial zones.
Group 2 rabbits demonstrated clefts extending to the tran-
sitional zone with normal cellularity in the transitional and
radial zones. Group 3 rabbits had normal cartilage surfaces
with normal cellularity in the transitional and radial zones
(Fig. 1). Histopathological scores were 1.4 in group 3 rabbits,
4.0 in group 2 rabbits, and 6.9 in group 1 rabbits. Group 3
scores were significantly lower than group 1 and 2 scores (P<
0.01), as seen in Table 1. 
Data are expressed as mean±SD (n=10).
*Significant differences compared with G1, P<0.01; 
� Significant differ-
ences compared with G1 and G2, P<0.01. 
Group
Lameness 
period (day)
Macroscopic
score
Histological
score
G1 26.0±2.7 4.6±0.7 6.9±0.8
G2 19.1±3.2* 2.9±0.5* 4.0±0.6*
G3 11.6±1.9
� 1.5±0.7
� 1.4±0.5
�
Table 1. Effects of hyaluronic acid (HA) and recombinant human
growth hormone (rhGH) on collagenase-induced osteoarthritis
in rabbits 
G1 G2 G3
Fig. 1. (A) Gross findings of the femoral condyles in Group 1 (G1), Group 2 (G2) and Group 3 (G3) rabbits. (B) histopathologic findings of
axial sections obtained at the rectangular areas shown in column A photographs (H&E staining, ×40). The loss of cartilage is seen on the
femoral condyles (black arrows).
A
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DISCUSSION 
The objective of this study was to evaluate the additive
effect of recombinant human GH to intra-articular HA treat-
ment. Unlike other joint conditions, OA is local disease res-
tricted to one or more joints. This unique feature provides
an opportunity for local intra-articular treatment without
the risk of systemic side effects (13). 
Articular cartilage and synovial fluid play an essential role
in the movement of joints. Synovial fluid provides an effec-
tive hydrodynamic lubricant by forming a thin viscous film
of low shear rates over the surface of the synovium and artic-
ular cartilage in the joint space. Articular cartilage spreads
compressive stresses over the articular plate surfaces of the
joint, thus protecting weight-bearing bones from shattering
or deteriorating. The cartilage matrix of joint is maintained
by a balance between the synthesis by chondrocyte and their
subsequent degradation by proteolytic enzymes from chon-
drocytes. Chronic disruption of this equilibrium is associat-
ed with the development of osteoarthritis (14, 15). HA con-
tributes to the viscoelastic property of synovial fluid that serves
as a lubricant and a shock absorber (16). It also plays an impor-
tant role in the maintenance and restoration of cartilage matrix
through inhibiting the formation of prostaglandins, induc-
ing proteoglycan aggregation, and modulating the inflam-
matory response (4-6). In OA, both the concentration and
molecular weight of intra-articular endogenous HA are dec-
reased (6). Intra-articular HA injection is widely recognized
as an effective treatment of OA. The efficacy of intra-articu-
lar HA injection can be influenced by molecular weight of
injected HA (16, 17). Molecules with higher molecular weights
may yield more superior clinical results than those with lower
molecular weights in OA treatment (11, 18). Considering
these molecular weight effects on efficacy, high molecular
weight HA (3.0×106 Dalton) was used in the present study. 
In the present study, injection of HA alone yielded better
clinical outcomes with less macroscopic and histopathologic
damage than the control group (Fig. 1, Table 1). However,
intra-articular HA injection did not fully restore the cartilage
defect in collagenase-induced OA (Fig. 1, Table 1). HA inject-
ed rabbits (group 2), demonstrated macroscopic erosions in
the knee cartilage and clefts extending to the transitional zone
in the histopathologic evaluation. There is previous report
that intra-articular HA injections were not effective in cases
with considerable effusion or in individuals with gross archi-
tectural changes (7). 
Combined therapy with HA and recombinant human GH
showed better results than HA alone in clinical observations
and macroscopic and histopathological findings. Articular
cartilage was completely healed and revealed normal surfaces
and cellularity in group 3 rabbits (Fig. 1, Table 1). In this
study, GH was given in a dose of 3 mg that is comparable
to dose used in GH deficit patients or previous reports about
the GH in the tibial fracture of rabbits (14).
Until recently, the effect of exogenous GH administration
in the process of skeletal repair remains controversial. Bak et
al. (14) studied 36 rats with closed diaphyseal tibial fractures
with intramedullary nailing. In this study, all rats received
subcutaneous recombinant human GH injections (1 mg) twice
per day. Significant improvement in maximal stiffness and
ultimate load-bearing were observed at evaluation performed
after 40 days of healing. Kolbeck et al. (19) reported that the
administration of homologous GH stimulates callus forma-
tion and ossification in the early phase of bone healing, which
consequently results in an increased mechanical strength and
stiffness. On the contrary, GH administration had no measur-
able effects on fracture healing in a standardized tibia osteoto-
my rabbit model (20). 
Kolbeck et al. (19) studied 23 dogs with experimentally-
induced 3 cm ulnar bone defects and intramedullary fixation.
Dogs were injected with recombinant bovine GH (1 mg),
and several of these GH-treated dogs had closure of these
bone defect while the remainder demonstrated healing. 
New form of angiogenesis, morphoangiogenesis, was report-
ed in the knee of adult rabbits with intra-articular GH injec-
tions for articulophyseal cartilage regeneration (9). Instead
of four layered daughter vessels identical to their parent ves-
sels in regular angiogenesis, capillaries with single layer fen-
estrated thin wall were formed by intra-articular growth hor-
mone induced morphoangiogenesis. Dunn (9) claimed that
this architecture is suitable for the production of stem cells
and regeneration of articulophyseal cartilage. In present study,
recombinant human GH was injected into intra-articular
spaces using the method similar to Dunn’s report (9), sug-
gesting the possible involvement of morphoangiogenesis in
the additive effects of GH to intra-articular HA injections.
Short residence time due to rapid uptake by circulation
imposes major challenge in intra-articular delivery of recom-
binant human GH (13). This emphasizes the need for the
development of sustained-release formulas that support the
continuous release of the drug from a depot in the joint space
over several weeks to months. 
Previously-marketed daily injections have provided distinct
peaks and troughs of GH concentrations over 24 hr. The phar-
macokinetic profile of recombinant GH is different from that
of normal physiologic GH with distinct bursts (21). Genetech
and Alkermes developed the Nutropin Depot
� as a sustained-
release human GH formulation using polylactic glycolic acid
(PLGA) microparticles for the first time. Nutropin Depot
�
seemed to achieve stable therapeutic IGF-1 target levels for
at least 14 days with higher efficacy and without supraphys-
iological GH concentrations at all times. Nutropin Depot
�
required the fewest injection number to achieve GH levels
within the target range, and appealed to patient in its con-
venience and compliance. However, the PLGA particle size
of microspheres was too large to be suspended efficiently in
an injection medium. Therefore, injections through a 21 to
23 gauge are inevitable. Complexities with long-acting pro-780 S.B. Kim, D.R. Kwon, H. Kwak, et al.
tein delivery system using PLGA include inflammation and
protein denaturation by hydrophobic interactions and harsh
acidic microenvironments. These complexities decrease the
bioavailability of Nutropin Depot
� (22).
The recombinant human GH used in the present study is
a sustained-release formula which induced continuous serum
IGF-1 elevation for 6 days after a single injection. This prod-
uct also exhibited greater than 95% bioavailability. Recom-
binant human GH in medium chain triglycerides can be eas-
ily injected through a 26 to 27 gauge needle due to the small
particle size and the localized lecithin on the microparticle
surfaces. However, considering that this study was conduct-
ed in a relatively short period to assess long-term effects, addi-
tional studies must be performed to assess the differences in
intra-articular dosage, formulations, and injection method
variability. 
In conclusion, our results suggest that co-injection of intra-
articular HA and recombinant human GH is more effective
than HA injections alone in an osteoarthritis model. Novel
combined therapy of HA with chondrocyte protective func-
tions and recombinant human GH with generative and con-
structive actions in OA affected joint can be promising treat-
ment option for OA. 
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